Immune-endothelial crosstalk in cardiovascular inflammation: Canakinumab at the intersection of mechanism and precision therapy
Anti-inflammatory therapy targeting immune-endothelial interactions offers precision medicine pathways for cardiovascular inflammation.
This review examines how canakinumab targets immune-endothelial crosstalk in cardiovascular inflammation, building on CANTOS trial evidence. It explores precision medicine applications for identifying patients most likely to benefit from anti-IL-1β therapy.
What the study was
- Study design
- Narrative review
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Biomedicine & Pharmacotherapy
Why it surfaced
Review of established therapy with no novel data; relevant to cardiovascular-metabolic topic.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.